Literature DB >> 18237600

Prognostic value of electrocardiographic measurements before and after cardiac resynchronization device implantation in patients with heart failure due to ischemic or nonischemic cardiomyopathy.

Mark A Iler1, Tingfei Hu, Sunil Ayyagari, Thomas D Callahan, Kenneth C Civello, Sergio G Thal, Bruce L Wilkoff, Mina K Chung.   

Abstract

Postimplant QRS narrowing may predict clinical response after cardiac resynchronization therapy (CRT), but identification of nonresponders remains difficult. We studied the predictive value of electrocardiographic characteristics for mortality or cardiac transplantation in patients after CRT. Patients who had electrocardiograms available for review from before and after CRT device implantation were identified from a clinical database. Bivariate and multivariate Cox regression analyses were performed for the end point of death or transplantation. Of 337 patients (age 65+/-12 years, 76% men, left ventricular ejection fraction 22+/-12%, pre-QRS 175+/-30 ms), 84 died and 7 underwent transplantation during a follow-up of 27+/-15 months. Variables predictive of death or transplantation included QRS increase after CRT (45% vs 32%, p=0.03), older age, higher New York Heart Association class, lower left ventricular ejection fraction, and higher tertile of postimplant QRS (p=0.04), but not preimplant rhythm, QRS duration, or QRS morphology. After adjusting for confounding variables, independent predictors of mortality were older age (hazard ratio [HR] 1.03, 95% confidence interval [CI] 1.00 to 1.05, p=0.04), lack of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (HR 2.17, 95% CI 1.16 to 4.08, p<0.02), and longer postimplant QRS by tertile (HR 1.50, 95% CI 1.09 to 2.05, p=0.01). In conclusion, wider QRS after CRT device implantation is an independent predictor of mortality or transplantation. In patients with increased QRS durations despite CRT, closer follow-up or reassessment for alternative management strategies may be warranted.

Entities:  

Mesh:

Year:  2007        PMID: 18237600     DOI: 10.1016/j.amjcard.2007.08.043

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  The year of 2008 in electrocardiology.

Authors:  Shlomo Stern
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-01       Impact factor: 1.468

2.  ICD lead type and RV lead position in CRT-D recipients.

Authors:  Alexander P Benz; Mate Vamos; Julia W Erath; Peter Bogyi; Gabor Z Duray; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2018-05-24       Impact factor: 5.460

3.  Native QRS narrowing reflects electrical reversal and associates with anatomical reversal in cardiac resynchronization therapy.

Authors:  Xin-wei Yang; Wei Hua; Jing Wang; Zhi-min Liu; Li-gang Ding; Ke-ping Chen; Shu Zhang
Journal:  J Interv Card Electrophysiol       Date:  2014-09-17       Impact factor: 1.900

4.  Association of QRS narrowing with response to cardiac resynchronization therapy-a systematic review and meta-analysis of observational studies.

Authors:  George Bazoukis; Katerina K Naka; Alawi Alsheikh-Ali; Gary Tse; Konstantinos P Letsas; Panagiotis Korantzopoulos; Tong Liu; Cynthia Yeung; Michael Efremidis; Konstantinos Tsioufis; Adrian Baranchuk; Stavros Stavrakis
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

5.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

Review 6.  Optimal site selection and image fusion guidance technology to facilitate cardiac resynchronization therapy.

Authors:  Benjamin J Sieniewicz; Justin Gould; Bradley Porter; Baldeep S Sidhu; Jonathan M Behar; Simon Claridge; Steve Niederer; Christopher A Rinaldi
Journal:  Expert Rev Med Devices       Date:  2018-07-30       Impact factor: 3.166

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.